Citizens has again affirmed a Market Outperform recommendation for Kura Oncology, maintaining a $24.00 price target on the stock. That target equates to almost 200% upside from the quoted market price of $8.12, and the firm’s note references a discounted earnings-per-share and revenue multiple approach underpinning the valuation.
The analyst reaffirmation comes after Kura’s recent presentation of its outlook for 2026 and follows updates on the early launch of KOMZIFTI (ziftomenib). Citizens emphasized the company’s set of clinical and commercial milestones, including progress across its FTI program and next-generation menin inhibitor pipeline, as core elements of the investment thesis.
In its note, Citizens compared Kura’s commercialization prospects with those of competitor Syndax, suggesting Kura could capture a marginally larger share of the long-term market as it executes on its commercial strategy. The firm pointed to the roughly $7 billion addressable acute myeloid leukemia market as the backdrop for Kura’s ambitions.
On the financial front, Citizens highlighted a pro forma cash position of $667.3 million, which the firm said is sufficient to fully fund Kura’s frontline AML trials while supporting ongoing clinical development of the FTI program and early commercial activities following the company’s first drug approval. The firm also noted a market capitalization of $706.58 million and a free cash flow yield of 12%.
Liquidity metrics cited in the note include a current ratio of 5.12, which InvestingPro data indicates, showing liquid assets substantially exceed near-term liabilities. Citizens’ valuation sits alongside a broader analyst consensus that averages to a 1.4 buy recommendation on the 1-to-5 scale where 1 denotes Strong Buy.
Commercial progress for KOMZIFTI has produced a material near-term cash event: Kura completed the first U.S. commercial sale of KOMZIFTI, triggering a $135 million milestone payment from partner Kyowa Kirin Co., Ltd. The company expects to receive that payment before the end of the year. KOMZIFTI received U.S. Food and Drug Administration approval on November 13, 2025, and has been incorporated into the National Comprehensive Cancer Network Clinical Practice Guidelines as a Category 2A recommended treatment for adults with relapsed or refractory AML with NPM1 mutation.
Citizens underscored potential clinical advantages of ziftomenib, particularly for older and more complex AML patients, as part of its rationale for maintaining the Market Outperform stance and $24.00 target. The firm also relied on a discounted EPS and revenue multiple framework after reviewing Kura’s 2026 outlook.
Investors should note that Citizens’ view is consistent with valuation data that shows the stock trading below its Fair Value, according to InvestingPro. The firm also referenced the availability of an expanded Pro Research Report covering Kura and more than 1,400 other U.S. equities for deeper analysis.
Quick facts
- Current share price cited: $8.12
- Citizens price target: $24.00
- Implied upside: nearly 200%
- Pro forma cash: $667.3 million
- Market capitalization: $706.58 million
- Free cash flow yield: 12%
- Current ratio (InvestingPro): 5.12
- Milestone payment triggered from Kyowa Kirin: $135 million, expected before year end
- KOMZIFTI FDA approval date: November 13, 2025
- NCCN designation: Category 2A for relapsed/refractory AML with NPM1 mutation